Antimicrobial resistance prevention initiative-an update: Proceedings of an expert panel on resistance

American Journal of Infection Control

Volumn 35, Issue 9, 2007, Pages S1-

  Moellering Jr , Robert C ^a   Graybill, John R ^b   McGowan Jr , John E ^c   Corey, Lawrence ^d,e  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c EMORY UNIVERSITY   (United States)

^d Virology Division   (United States)

^e Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALPHA INTERFERON; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CARBAPENEM; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; CLAVULANIC ACID; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; FAMCICLOVIR; FLUCONAZOLE; FOSCARNET; MONOBACTAM DERIVATIVE; PENCICLOVIR; PENICILLIN G; POLYENE ANTIBIOTIC AGENT; POLYMYXIN B; POSACONAZOLE; QUINOLONE DERIVATIVE; RIFAMPICIN; TRIFLURIDINE; UNINDEXED DRUG; VALACICLOVIR; VORICONAZOLE;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ARTICLE; ASPERGILLOSIS; ASPERGILLUS; ASPERGILLUS TERREUS; AVIAN INFLUENZA; BACTERIAL INFECTION; CANDIDA ALBICANS; CANDIDIASIS; CROSS RESISTANCE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG SENSITIVITY; GENITAL HERPES; GRAFT REJECTION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HERPES SIMPLEX VIRUS; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HERPES VIRUS; HERPES ZOSTER; HOSPITAL INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; INFLUENZA VIRUS A; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MYCOSIS; NONHUMAN; PANDEMIC; PATHOGENICITY; VARICELLA ZOSTER VIRUS; VIRUS INFECTION; VIRUS RESISTANCE; VIRUS STRAIN;

EID: 35548959138     PISSN: 01966553     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajic.2007.08.001     Document Type: Article

References (228)

1. Antimicrobial Resistance Prevention Initiative. Available at: http://www.icaac.org/arpi.htm. Accessed October 6, 2006.
2. Clavel F., and Hance A.J. HIV drug resistance. N Engl J Med 350 (2004) 1023-1035
3. de Jong M.D., Tran T.T., Truong H.K., et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 353 (2005) 2667-2672
4. Tenover F.C. Mechanisms of antimicrobial resistance in bacteria. Am J Med 119 Suppl 1 (2006) S3-S10 discussion S62-70
5. Rybak M.J. Pharmacodynamics: relation to antimicrobial resistance. Am J Med 119 Suppl 1 (2006) S37-S44 discussion S62-70
6. Rice L.B. Antimicrobial resistance in gram-positive bacteria. Am J Med 119 Suppl 1 (2006) S11-S19 discussion S62-70
7. McGowan Jr. J.E. Resistance in nonfermenting gram-negative bacteria: multidrug resistance to the maximum. Am J Med 119 Suppl 1 (2006) S29-S36 discussion S62-70
8. Paterson D.L. Resistance in gram-negative bacteria: enterobacteriaceae. Am J Med 119 Suppl 1 (2006) S20-S28 discussion S62-70
9. Henderson D.K. Managing methicillin-resistant staphylococci: a paradigm for preventing nosocomial transmission of resistant organisms. Am J Med 119 Suppl 1 (2006) S45-S52 discussion S62-70
10. Fishman N. Antimicrobial stewardship. Am J Med 119 (2006) S53-S61 discussion S62-70
11. Siegel J.D., Rhinehart E., Jackson M., Chiarello L., Healthcare Infection Control Practices Advisory Committee, and Centers for Disease Control and Prevention. Management of Multidrug-Resistant Organisms in Healthcare Settings, 2006 (2006), Centers for Disease Control and Prevention, Healthcare Infection Control Practices Advisory Committee (HICPAC), Atlanta, GA. http://www.cdc.gov/ncidod/dhqp/pdf/ar/mdroGuideline2006.pdf Accessed April 9, 2007
12. Talbot G.H., Bradley J., Edwards Jr. J.E., Gilbert D., Scheld M., and Bartlett J.G. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 42 (2006) 657-668
13. Patterson J.E. Multidrug-resistant gram-negative pathogens: multiple approaches and measures for prevention. Infect Control Hosp Epidemiol 27 (2006) 889-892
14. Wisplinghoff H., Bischoff T., Tallent S.M., Seifert H., Wenzel R.P., and Edmond M.B. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 39 (2004) 309-317
15. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004: a report from the NNIS System. Am J Infect Control 32 (2004) 470-485
16. McDonald L.C. Trends in antimicrobial resistance in health care-associated pathogens and effect on treatment. Clin Infect Dis 42 Suppl 2 (2006) S65-S71
17. Crum N.F., Lee R.U., Thornton S.A., et al. Fifteen-year study of the changing epidemiology of methicillin-resistant Staphylococcus aureus. Am J Med 119 (2006) 943-951
18. Craven D.E., and Shapiro D.S. Staphylococcus aureus: times, they are a-changin'. Clin Infect Dis 42 (2006) 179-180
19. Gaynes R., and Edwards J.R. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis 41 (2005) 848-854
20. Miller L.G., Perdreau-Remington F., Bayer A.S., et al. Clinical and epidemiologic characteristics cannot distinguish community-associated methicillin-resistant Staphylococcus aureus infection from methicillin-susceptible S. aureus infection: a prospective investigation. Clin Infect Dis 44 (2007) 471-482
21. Fridkin S.K., Hageman J.C., Morrison M., et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 352 (2005) 1436-1444
22. Kazakova S.V., Hageman J.C., Matava M., et al. A clone of methicillin-resistant Staphylococcus aureus among professional football players. N Engl J Med 352 (2005) 468-475
23. Chambers H.F. Community-associated MRSA-resistance and virulence converge. N Engl J Med 352 (2005) 1485-1487
24. Grundmann H., Aires-de-Sousa M., Boyce J., and Tiemersma E. Emergence and resurgence of methicillin-resistant Staphylococcus aureus as a public-health threat. Lancet 368 (2006) 874-885
25. Gould I.M. Community-acquired MRSA: can we control it?. Lancet 368 (2006) 824-826
26. Klevens R.M., Edwards J.R., Tenover F.C., McDonald L.C., Horan T., and Gaynes R. Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992-2003. Clin Infect Dis 42 (2006) 389-391
27. Tenover F.C., McDougal L.K., Goering R.V., et al. Characterization of a strain of community-associated methicillin-resistant Staphylococcus aureus widely disseminated in the United States. J Clin Microbiol 44 (2006) 108-118
28. King M.D., Humphrey B.J., Wang Y.F., Kourbatova E.V., Ray S.M., and Blumberg H.M. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann Intern Med 144 (2006) 309-317
29. Diep B.A., Carleton H.A., Chang R.F., Sensabaugh G.F., and Perdreau-Remington F. Roles of 34 virulence genes in the evolution of hospital- and community-associated strains of methicillin-resistant Staphylococcus aureus. J Infect Dis 193 (2006) 1495-1503
30. Voyich J.M., Otto M., Mathema B., et al. Is Panton-Valentine leukocidin the major virulence determinant in community-associated methicillin-resistant Staphylococcus aureus disease?. J Infect Dis 194 (2006) 1761-1770
31. Miller L.G., Perdreau-Remington F., Rieg G., et al. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med 352 (2005) 1445-1453
32. Francis J.S., Doherty M.C., Lopatin U., et al. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis 40 (2005) 100-107
33. Kuehnert M.J., Kruszon-Moran D., Hill H.A., et al. Prevalence of Staphylococcus aureus nasal colonization in the United States, 2001-2002. J Infect Dis 193 (2006) 172-179
34. Hidron A.I., Kourbatova E.V., Halvosa J.S., et al. Risk factors for colonization with methicillin-resistant Staphylococcus aureus (MRSA) in patients admitted to an urban hospital: emergence of community-associated MRSA nasal carriage. Clin Infect Dis 41 (2005) 159-166
35. McCaig L.F., McDonald L.C., Mandal S., and Jernigan D.B. Staphylococcus aureus-associated skin and soft tissue infections in ambulatory care. Emerg Infect Dis 12 (2006) 1715-1722
36. Moran G.J., Krishnadasan A., Gorwitz R.J., et al. Methicillin-resistant S aureus infections among patients in the emergency department. N Engl J Med 355 (2006) 666-674
37. Lescure F.X., Locher G., Eveillard M., et al. Community-acquired infection with healthcare-associated methicillin-resistant Staphylococcus aureus: the role of home nursing care. Infect Control Hosp Epidemiol 27 (2006) 1213-1218
38. Gould C.V., Rothenberg R., and Steinberg J.P. Antibiotic resistance in long-term acute care hospitals: the perfect storm. Infect Control Hosp Epidemiol 27 (2006) 920-925
39. Grayson M.L. The treatment triangle for staphylococcal infections. N Engl J Med 355 (2006) 724-727
40. Steward C.D., Raney P.M., Morrell A.K., et al. Testing for induction of clindamycin resistance in erythromycin-resistant isolates of Staphylococcus aureus. J Clin Microbiol 43 (2005) 1716-1721
41. Appelbaum P.C. MRSA-the tip of the iceberg. Clin Microbiol Infect 12 Suppl 2 (2006) 3-10
42. Zetola N., Francis J.S., Nuermberger E.L., and Bishai W.R. Community-acquired methicillin-resistant Staphylococcus aureus: an emerging threat. Lancet Infect Dis 5 (2005) 275-286
43. Shorr A.F., Jackson W.L., and Lipman J. Making the wrong choice: consequences for patients with infections due to methicillin-resistant Staphylococcus aureus. Crit Care Med 34 (2006) 2239-2241
44. Sigurdardottir B., Berg J.V., Hu J., et al. Descriptive epidemiology and case-control study of patients colonized with vancomycin-resistant enterococcus and methicillin-resistant Staphylococcus aureus. Infect Control Hosp Epidemiol 27 (2006) 913-919
45. Seybold U., Kourbatova E.V., Johnson J.G., et al. Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care-associated blood stream infections. Clin Infect Dis 42 (2006) 647-656
46. Roghmann M.C., and McGrail L. Novel ways of preventing antibiotic-resistant infections: what might the future hold?. Am J Infect Control 34 (2006) 469-475
47. Gerber S.I., Jones R.C., Scott M.V., et al. Management of outbreaks of methicillin-resistant Staphylococcus aureus infection in the neonatal intensive care unit: a consensus statement. Infect Control Hosp Epidemiol 27 (2006) 139-145
48. Kourbatova E.V., Halvosa J.S., King M.D., Ray S.M., White N., and Blumberg H.M. Emergence of community-associated methicillin-resistant Staphylococcus aureus USA 300 clone as a cause of health care-associated infections among patients with prosthetic joint infections. Am J Infect Control 33 (2005) 385-391
49. Coia J.E., Duckworth G.J., Edwards D.I., et al. Guidelines for the control and prevention of methicillin-resistant Staphylococcus aureus (MRSA) in healthcare facilities. J Hosp Infect 63 Suppl 1 (2006) S1-S44
50. Huijsdens X.W., van Santen-Verheuvel M.G., Spalburg E., et al. Multiple cases of familial transmission of community-acquired methicillin-resistant Staphylococcus aureus. J Clin Microbiol 44 (2006) 2994-2996
51. Rozenbaum R., Silva-Carvalho M.C., Souza R.R., et al. Molecular characterization of methicillin-resistant Staphylococcus aureus disseminated in a home care system. Infect Control Hosp Epidemiol 27 (2006) 1041-1050
52. Falagas M.E., Koletsi P.K., and Bliziotis I.A. The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J Med Microbiol 55 (2006) 1619-1629
53. Moland E.S., Hanson N.D., Black J.A., Hossain A., Song W., and Thomson K.S. Prevalence of newer β-lactamases in gram-negative clinical isolates collected in the United States from 2001 to 2002. J Clin Microbiol 44 (2006) 3318-3324
54. Paterson D.L. The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis 43 Suppl 2 (2006) S43-S48
55. Rodriguez-Bano J., Navarro M.D., Romero L., et al. Bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin Infect Dis 43 (2006) 1407-1414
56. Ben-Ami R., Schwaber M.J., Navon-Venezia S., et al. Influx of extended-spectrum β-lactamase-producing enterobacteriaceae into the hospital. Clin Infect Dis 42 (2006) 925-934
57. Schwaber M.J., Navon-Venezia S., Kaye K.S., Ben-Ami R., Schwartz D., and Carmeli Y. Clinical and economic impact of bacteremia with extended-spectrum β-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 50 (2006) 1257-1262
58. Lee S.Y., Kotapati S., Kuti J.L., Nightingale C.H., and Nicolau D.P. Impact of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella species on clinical outcomes and hospital costs: a matched cohort study. Infect Control Hosp Epidemiol 27 (2006) 1226-1232
59. Tumbarello M., Spanu T., Sanguinetti M., et al. Bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome. Antimicrob Agents Chemother 50 (2006) 498-504
60. Rodloff A.C., Goldstein E.J., and Torres A. Two decades of imipenem therapy. J Antimicrob Chemother 58 (2006) 916-929
61. ACT-1 β-lactamase production, porin OmpK35/36 insertional inactivation, and down-regulation of the phosphate transport porin phoe. Antimicrob Agents Chemother 50 (2006) 3396-3406
62. Rice L.B. Challenges in identifying new antimicrobial agents effective for treating infections with Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis 43 Suppl 2 (2006) S100-S105
63. Lartigue M.F., Poirel L., and Nordmann P. First detection of a carbapenem-hydrolyzing metalloenzyme in an Enterobacteriaceae isolate in France. Antimicrob Agents Chemother 48 (2004) 4929-4930
64. Fritsche T.R., Sader H.S., Toleman M.A., Walsh T.R., and Jones R.N. Emerging metallo- β-lactamase-mediated resistances: a summary report from the worldwide SENTRY antimicrobial surveillance program. Clin Infect Dis 41 Suppl 4 (2005) S276-S278
65. Mena A., Plasencia V., Garcia L., et al. Characterization of a large outbreak by CTX-M-1-producing Klebsiella pneumoniae and mechanisms leading to in vivo carbapenem resistance development. J Clin Microbiol 44 (2006) 2831-2837
66. Mainardi J.L., Mugnier P., Coutrot A., Buu-Hoi A., Collatz E., and Gutmann L. Carbapenem resistance in a clinical isolate of Citrobacter freundii. Antimicrob Agents Chemother 41 (1997) 2352-2354
67. Bratu S., Landman D., Alam M., Tolentino E., and Quale J. Detection of KPC carbapenem-hydrolyzing enzymes in Enterobacter spp. from Brooklyn, New York. Antimicrob Agents Chemother 49 (2005) 776-778
68. Hossain A., Ferraro M.J., Pino R.M., et al. Plasmid-mediated carbapenem-hydrolyzing enzyme KPC-2 in an Enterobacter sp. Antimicrob Agents Chemother 48 (2004) 4438-4440
69. Miriagou V., Tzouvelekis L.S., Rossiter S., Tzelepi E., Angulo F.J., and Whichard J.M. Imipenem resistance in a Salmonella clinical strain due to plasmid-mediated class A carbapenemase KPC-2. Antimicrob Agents Chemother 47 (2003) 1297-1300
70. Yigit H., Queenan A.M., Rasheed J.K., et al. Carbapenem-resistant strain of Klebsiella oxytoca harboring carbapenem-hydrolyzing β-lactamase KPC-2. Antimicrob Agents Chemother 47 (2003) 3881-3889
71. Yigit H., Queenan A.M., Anderson G.J., et al. Novel carbapenem-hydrolyzing β-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 45 (2001) 1151-1161
72. Smith Moland E., Hanson N.D., Herrera V.L., et al. Plasmid-mediated, carbapenem-hydrolysing β-lactamase, KPC-2, in Klebsiella pneumoniae isolates. J Antimicrob Chemother 51 (2003) 711-714
73. Woodford N., Tierno Jr. P.M., Young K., et al. Outbreak of Klebsiella pneumoniae producing a new carbapenem-hydrolyzing class A β-lactamase, KPC-3, in a New York Medical Center. Antimicrob Agents Chemother 48 (2004) 4793-4799
74. Bratu S., Landman D., Haag R., et al. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch Intern Med 165 (2005) 1430-1435
75. Bratu S., Mooty M., Nichani S., et al. Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn, New York: epidemiology and recommendations for detection. Antimicrob Agents Chemother 49 (2005) 3018-3020
76. Bratu S., Tolaney P., Karumudi U., et al. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. J Antimicrob Chemother 56 (2005) 128-132
77. Lomaestro B.M., Tobin E.H., Shang W., and Gootz T. The spread of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae to upstate New York. Clin Infect Dis 43 (2006) e26-e28
78. Pope J., Adams J., Doi Y., Szabo D., and Paterson D.L. KPC type β-lactamase, rural Pennsylvania. Emerg Infect Dis 12 (2006) 1613-1614
79. Deshpande L.M., Rhomberg P.R., Sader H.S., and Jones R.N. Emergence of serine carbapenemases (KPC and SME) among clinical strains of Enterobacteriaceae isolated in the United States Medical Centers: report from the MYSTIC Program (1999-2005). Diagn Microbiol Infect Dis 56 (2006) 367-372
80. Navon-Venezia S., Chmelnitsky I., Leavitt A., Schwaber M.J., Schwartz D., and Carmeli Y. Plasmid-mediated imipenem-hydrolyzing enzyme KPC-2 among multiple carbapenem-resistant Escherichia coli clones in Israel. Antimicrob Agents Chemother 50 (2006) 3098-3101
81. Naas T., Nordmann P., Vedel G., and Poyart C. Plasmid-mediated carbapenem-hydrolyzing β-lactamase KPC in a Klebsiella pneumoniae isolate from France. Antimicrob Agents Chemother 49 (2005) 4423-4424
82. Virginia Villegas M., Lolans K., Correa A., et al. First detection of the plasmid-mediated class A carbapenemase KPC-2 in clinical isolates of Klebsiella pneumoniae from South America. Antimicrob Agents Chemother 50 (2006) 2880-2882
83. Lee S.H., Jeong S.H., and Cha S.S. Screening for carbapenem-resistant gram-negative bacteria. Lancet Infect Dis 6 (2006) 682-684
84. Tenover F.C., Kalsi R.K., Williams P.P., et al. Carbapenem resistance in Klebsiella pneumoniae not detected by automated susceptibility testing. Emerg Infect Dis 12 (2006) 1209-1213
85. Abbo A., Navon-Venezia S., Hammer-Muntz O., Krichali T., Siegman-Igra Y., and Carmeli Y. Multidrug-resistant Acinetobacter baumannii. Emerg Infect Dis 11 (2005) 22-29
86. Poirel L., and Nordmann P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect 12 (2006) 826-836
87. El Shafie S.S., Alishaq M., and Leni Garcia M. Investigation of an outbreak of multidrug-resistant Acinetobacter baumannii in trauma intensive care unit. J Hosp Infect 56 (2004) 101-105
88. Zapor M.J., and Moran K.A. Infectious diseases during wartime. Curr Opin Infect Dis 18 (2005) 395-399
89. Hujer K.M., Hujer A.M., Hulten E.A., et al. Analysis of antibiotic resistance genes in multidrug-resistant Acinetobacter sp. isolates from military and civilian patients treated at the Walter Reed Army Medical Center. Antimicrob Agents Chemother 50 (2006) 4114-4123
90. Peleg A.Y., Franklin C., Bell J.M., and Spelman D.W. Emergence of carbapenem resistance in Acinetobacter baumannii recovered from blood cultures in Australia. Infect Control Hosp Epidemiol 27 (2006) 759-761
91. Timurkaynak F., Can F., Azap O.K., Demirbilek M., Arslan H., and Karaman S.O. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units. Int J Antimicrob Agents 27 (2006) 224-228
92. Ying C.M., Ling T.K., Lee C.C., and Ling J.M. Characterization of carbapenem-resistant Acinetobacter baumannii in Shanghai and Hong Kong. J Med Microbiol 55 (2006) 799-802
93. Jeon B.C., Jeong S.H., Bae I.K., et al. Investigation of a nosocomial outbreak of imipenem-resistant Acinetobacter baumannii producing the OXA-23 β-lactamase in Korea. J Clin Microbiol 43 (2005) 2241-2245
94. Pournaras S., Markogiannakis A., Ikonomidis A., et al. Outbreak of multiple clones of imipenem-resistant Acinetobacter baumannii isolates expressing OXA-58 carbapenemase in an intensive care unit. J Antimicrob Chemother 57 (2006) 557-561
95. del Mar Tomas M., Cartelle M., Pertega S., et al. Hospital outbreak caused by a carbapenem-resistant strain of Acinetobacter baumannii: patient prognosis and risk-factors for colonisation and infection. Clin Microbiol Infect 11 (2005) 540-546
96. Turton J.F., Kaufmann M.E., Warner M., et al. A prevalent, multiresistant clone of Acinetobacter baumannii in Southeast England. J Hosp Infect 58 (2004) 170-179
97. Dalla-Costa L.M., Coelho J.M., Souza H.A., et al. Outbreak of carbapenem-resistant Acinetobacter baumannii producing the OXA-23 enzyme in Curitiba. Brazil. J Clin Microbiol 41 (2003) 3403-3406
98. Fournier P.E., and Richet H. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis 42 (2006) 692-699
99. Bonomo R.A., and Szabo D. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis 43 Suppl 2 (2006) S49-S56
100. Falagas M.E., and Kopterides P. Risk factors for the isolation of multi-drug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa: a systematic review of the literature. J Hosp Infect 64 (2006) 7-15
101. Rahal J.J. Novel antibiotic combinations against infections with almost completely resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis 43 Suppl 2 (2006) S95-S99
102. Stein G.E., and Craig W.A. Tigecycline: a critical analysis. Clin Infect Dis 43 (2006) 518-524
103. Peleg A.Y., Potoski B.A., Rea R., et al. Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J Antimicrob Chemother 59 (2007) 128-131
104. Goold P.C., and Bignell C.J. No way back for quinolones in the treatment of gonorrhoea. Sex Transm Infect 82 (2006) 225-226
105. White C. New gonorrhoea strains are resistant to antibiotics. [news roundup]. BMJ 333 (2006) 825
106. Ghanem K.G., Giles J.A., and Zenilman J.M. Fluoroquinolone-resistant Neisseria gonorrhoeae: the inevitable epidemic. Infect Dis Clin North Am 19 (2005) 351-365
107. Ito M., Yasuda M., Yokoi S., et al. Remarkable increase in central Japan in 2001-2002 of Neisseria gonorrhoeae isolates with decreased susceptibility to penicillin, tetracycline, oral cephalosporins, and fluoroquinolones. Antimicrob Agents Chemother 48 (2004) 3185-3187
108. Shigemura K., Shirakawa T., Okada H., et al. Mutations in the gyrA and parC genes and in vitro activities of fluoroquinolones in 91 clinical isolates of Neisseria gonorrhoeae in Japan. Sex Transm Dis 31 (2004) 180-184
109. Centers for Disease Control and Prevention (CDC). Update to CDC's Sexually Transmitted Diseases Treatment Guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections. MMWR Morb Mortal Wkly Rep 56 (2007) 332-336
110. Tapsall J. Antibiotic resistance in Neisseria gonorrhoeae is diminishing available treatment options for gonorrhea: some possible remedies. Expert Rev Anti Infect Ther 4 (2006) 619-628
111. Saha D., Karim M.M., Khan W.A., Ahmed S., Salam M.A., and Bennish M.L. Single-dose azithromycin for the treatment of cholera in adults. N Engl J Med 354 (2006) 2452-2462
112. Guerrant R.L. Cholera-still teaching hard lessons. N Engl J Med 354 (2006) 2500-2502
113. Sack D.A., Sack R.B., and Chaignat C.L. Getting serious about cholera. N Engl J Med 355 (2006) 649-651
114. Dechet A.M., Scallan E., Gensheimer K., et al. Outbreak of multidrug-resistant Salmonella enterica serotype Typhimurium Definitive Type 104 infection linked to commercial ground beef, northeastern United States, 2003-2004. Clin Infect Dis 42 (2006) 747-752
115. Maki D.G. Don't eat the spinach-controlling foodborne infectious disease. N Engl J Med 355 (2006) 1952-1955
116. Harris A.D., McGregor J.C., and Furuno J.P. What infection control interventions should be undertaken to control multidrug-resistant gram-negative bacteria?. Clin Infect Dis 43 Suppl 2 (2006) S57-S61
117. Salgado C.D., O'Grady N., and Farr B.M. Prevention and control of antimicrobial-resistant infections in intensive care patients. Crit Care Med 33 (2005) 2373-2382
118. Zillich A.J., Sutherland J.M., Wilson S.J., et al. Antimicrobial use control measures to prevent and control antimicrobial resistance in US hospitals. Infect Control Hosp Epidemiol 27 (2006) 1088-1095
119. Richardson M.D. Changing patterns and trends in systemic fungal infections. J Antimicrob Chemother 56 Suppl 1 (2005) i5-i11
120. Edmond M.B., Wallace S.E., McClish D.K., Pfaller M.A., Jones R.N., and Wenzel R.P. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 29 (1999) 239-244
121. Pfaller M.A., Diekema D.J., Jones R.N., et al. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol 39 (2001) 3254-3259
122. Ostrosky-Zeichner L., and Pappas P.G. Invasive candidiasis in the intensive care unit. Crit Care Med 34 (2006) 857-863
123. Wey S.B., Mori M., Pfaller M.A., Woolson R.F., and Wenzel R.P. Risk factors for hospital-acquired candidemia: a matched case-control study. Arch Intern Med 149 (1989) 2349-2353
124. Gudlaugsson O., Gillespie S., Lee K., et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 37 (2003) 1172-1177
125. Rex J.H., Bennett J.E., Sugar A.M., et al., Candidemia Study Group and the National Institute. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 331 (1994) 1325-1330
126. Rex J.H., Pappas P.G., Karchmer A.W., et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 36 (2003) 1221-1228
127. Clark T.A., and Hajjeh R.A. Recent trends in the epidemiology of invasive mycoses. Curr Opin Infect Dis 15 (2002) 569-574
128. Kauffman C.A. Zygomycosis: reemergence of an old pathogen. Clin Infect Dis 39 (2004) 588-590
129. Nucci M. Emerging moulds: Fusarium, Scedosporium and Zygomycetes in transplant recipients. Curr Opin Infect Dis 16 (2003) 607-612
130. Roden M.M., Zaoutis T.E., Buchanan W.L., et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 41 (2005) 634-653
131. Galgiani J.N., Catanzaro A., Cloud G.A., et al., Mycoses Study Group. Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis: a randomized, double-blind trial. Ann Intern Med 133 (2000) 676-686
132. Galgiani J.N., Ampel N.M., Blair J.E., et al. Coccidioidomycosis. Clin Infect Dis 41 (2005) 1217-1223
133. Pfaller M.A., Diekema D.J., and Sheehan D.J. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev 19 (2006) 435-447
134. Rex J.H., Pfaller M.A., Walsh T.J., et al. Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev 14 (2001) 643-658, table of contents
135. Rex J.H., Pfaller M.A., Galgiani J.N., et al., Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Clin Infect Dis 24 (1997) 235-247
136. Pfaller M.A., Boyken L., Hollis R.J., Messer S.A., Tendolkar S., and Diekema D.J. In vitro susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species to itraconazole: global survey of 9,359 isolates tested by clinical and laboratory standards institute broth microdilution methods. J Clin Microbiol 43 (2005) 3807-3810
137. Pfaller M.A., Messer S.A., Boyken L., et al. Use of fluconazole as a surrogate marker to predict susceptibility and resistance to voriconazole among 13,338 clinical isolates of Candida spp. tested by Clinical and Laboratory Standards Institute-recommended broth microdilution methods. J Clin Microbiol 45 (2007) 70-75
138. th International Conference on Antimicrobial Agents and Chemotherapy; September 27-30, 2006; San Francisco, CA. Abstract M-1590.
139. Andes D. Clinical utility of antifungal pharmacokinetics and pharmacodynamics. Curr Opin Infect Dis 17 (2004) 533-540
140. Takakura S., Fujihara N., Saito T., Kudo T., Iinuma Y., and Ichiyama S. Clinical factors associated with fluconazole resistance and short-term survival in patients with Candida bloodstream infection. Eur J Clin Microbiol Infect Dis 23 (2004) 380-388
141. Clancy C.J., Yu V.L., Morris A.J., Snydman D.R., and Nguyen M.H. Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia. Antimicrob Agents Chemother 49 (2005) 3171-3177
142. Lee S.C., Fung C.P., Huang J.S., et al. Clinical correlates of antifungal macrodilution susceptibility test results for non-AIDS patients with severe Candida infections treated with fluconazole. Antimicrob Agents Chemother 44 (2000) 2715-2718
143. Ruhnke M. Epidemiology of Candida albicans infections and role of non-Candida-albicans yeasts. Curr Drug Targets 7 (2006) 495-504
144. Pfaller M.A., Diekema D.J., Rex J.H., et al. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J Clin Microbiol 44 (2006) 819-826
145. Keating G.M. Posaconazole. Drugs 65 (2005) 1553-1567 discussion 1568-9
146. Lupetti A., Danesi R., Campa M., Del Tacca M., and Kelly S. Molecular basis of resistance to azole antifungals. Trends Mol Med 8 (2002) 76-81
147. Sanglard D., and Odds F.C. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis 2 (2002) 73-85
148. Ostrosky-Zeichner L., Rex J.H., Pappas P.G., et al. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 47 (2003) 3149-3154
149. Mora-Duarte J., Betts R., Rotstein C., et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 347 (2002) 2020-2029
150. Hernandez S., Lopez-Ribot J.L., Najvar L.K., McCarthy D.I., Bocanegra R., and Graybill J.R. Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob Agents Chemother 48 (2004) 1382-1383
151. Brzankalski GE, McCarthy DI, Fothergill AW, et al. In vitro activity of aminocandin (AC) against clinical isolates of Candida glabrata (CG). Presented at the 46th annual meeting of Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 20-27, 2006; San Francisco, CA. Abstract M1624.
152. Pfaller M.A., Messer S.A., Hollis R.J., Jones R.N., and Diekema D.J. In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrob Agents Chemother 46 (2002) 1723-1727
153. Xiao L., Madison V., Chau A.S., Loebenberg D., Palermo R.E., and McNicholas P.M. Three-dimensional models of wild-type and mutated forms of cytochrome P450 14alpha-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding. Antimicrob Agents Chemother 48 (2004) 568-574
154. Perfect J.R., Marr K.A., Walsh T.J., et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 36 (2003) 1122-1131
155. Lass-Florl C., Kofler G., Kropshofer G., et al. In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis. J Antimicrob Chemother 42 (1998) 497-502
156. Steinbach W.J., Benjamin Jr. D.K., Kontoyiannis D.P., et al. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis 39 (2004) 192-198
157. Lass-Florl C., Griff K., Mayr A., et al. Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience. Br J Haematol 131 (2005) 201-207
158. Lionakis M.S., Lewis R.E., Torres H.A., Albert N.D., Raad II, and Kontoyiannis D.P. Increased frequency of non-fumigatus Aspergillus species in amphotericin B- or triazole-pre-exposed cancer patients with positive cultures for aspergilli. Diagn Microbiol Infect Dis 52 (2005) 15-20
159. Siwek G.T., Dodgson K.J., de Magalhaes-Silverman M., et al. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis 39 (2004) 584-587
160. Siwek G, Diekema D, Polgreen P, Magalheas-Silverman M, Hoth P, Pfaller M. Reduction in incidence of invasive aspergillosis (IA) among hematopoietic stem cell transplant (HSCT) patients receiving voriconazole (VORI) prophylaxis: 2 year experience at a large teaching hospital. Presented at the 15th annual Focus on Fungal Infections conference; March 16-18, 2005; Miami, FL.
161. Imhof A., Balajee S.A., Fredricks D.N., Englund J.A., and Marr K.A. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 39 (2004) 743-746
162. Smith J., Safdar N., Knasinski V., et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 50 (2006) 1570-1572
163. Ezzet F., Wexler D., Courtney R., Krishna G., Lim J., and Laughlin M. Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Clin Pharmacokinet 44 (2005) 211-220
164. Walsh T.J., Raad I., Patterson T.F., et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 44 (2007) 2-12
165. Wiederhold N.P., Kontoyiannis D.P., Chi J., Prince R.A., Tam V.H., and Lewis R.E. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J Infect Dis 190 (2004) 1464-1471
166. Patterson T.F., Kirkpatrick W.R., White M., et al., I3 Aspergillus Study Group. Invasive aspergillosis: disease spectrum, treatment practices, and outcomes. Medicine (Baltimore) 79 (2000) 250-260
167. Lin S.J., Schranz J., and Teutsch S.M. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 32 (2001) 358-366
168. Pappas PG, Alexander B, Marr KA, et al. Invasive fungal infections (IFIs) in hematopoietic stem cell (HSCTs) and organ transplant recipients (OTRs): overview of the TRANSNET database. In: Program and abstracts of the 42nd Annual Meeting of the Infectious Diseases Society of America (Boston). Alexandria, VA: Infectious Diseases Society of America, 2004:174. Abstract 671.
169. Bacon T.H., Levin M.J., Leary J.J., Sarisky R.T., and Sutton D. Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clin Microbiol Rev 16 (2003) 114-128
170. Fife K.H., Crumpacker C.S., Mertz G.J., Hill E.L., and Boone G.S. Recurrence and resistance patterns of herpes simplex virus following cessation of > or = 6 years of chronic suppression with acyclovir. Acyclovir Study Group. J Infect Dis 169 (1994) 1338-1341
171. Lehrman S.N., Douglas J.M., Corey L., and Barry D.W. Recurrent genital herpes and suppressive oral acyclovir therapy. Relation between clinical outcome and in-vitro drug sensitivity. Ann Intern Med 104 (1986) 786-790
172. Reyes M., Shaik N.S., Graber J.M., et al. Acyclovir-resistant genital herpes among persons attending sexually transmitted disease and human immunodeficiency virus clinics. Arch Intern Med 163 (2003) 76-80
173. Meignier B., Longnecker R., Mavromara-Nazos P., Sears A.E., and Roizman B. Virulence of and establishment of latency by genetically engineered deletion mutants of herpes simplex virus 1. Virology 162 (1988) 251-254
174. Stanberry L.R., Kit S., and Myers M.G. Thymidine kinase-deficient herpes simplex virus type 2 genital infection in guinea pigs. J Virol 55 (1985) 322-328
175. Crumpacker C.S., Schnipper L.E., Zaia J.A., and Levin M.J. Growth inhibition by acycloguanosine of herpesviruses isolated from human infections. Antimicrob Agents Chemother 15 (1979) 642-645
176. Coen D.M. Acyclovir-resistant, pathogenic herpesviruses. Trends Microbiol 2 (1994) 481-485
177. Morfin F., and Thouvenot D. Herpes simplex virus resistance to antiviral drugs. J Clin Virol 26 (2003) 29-37
178. Kost R.G., Hill E.L., Tigges M., and Straus S.E. Brief report: recurrent acyclovir-resistant genital herpes in an immunocompetent patient. N Engl J Med 329 (1993) 1777-1782
179. Gupta R., Hill E.L., McClernon D., et al. Acyclovir sensitivity of sequential herpes simplex virus type 2 isolates from the genital mucosa of immunocompetent women. J Infect Dis 192 (2005) 1102-1107
180. Sasadeusz J.J., and Sacks S.L. Spontaneous reactivation of thymidine kinase-deficient, acyclovir-resistant type-2 herpes simplex virus: masked heterogeneity or reversion?. J Infect Dis 174 (1996) 476-482
181. Dorsky D., Chatis P., and Crumpacker C. Functional expression of a cloned herpes simplex virus type 1 DNA polymerase gene. J Virol 61 (1987) 1704-1707
182. Erlich K.S., Mills J., Chatis P., et al. Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. N Engl J Med 320 (1989) 293-296
183. Erlich K.S., and Mills J. Other virus infections in AIDS. II. Herpes simplex virus. Immunol Ser 44 (1989) 534-554
184. Safrin S., Elbeik T., Phan L., et al. Correlation between response to acyclovir and foscarnet therapy and in vitro susceptibility result for isolates of herpes simplex virus from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 38 (1994) 1246-1250
185. Safrin S., Crumpacker C., Chatis P., et al., AIDS Clinical Trials Group. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. N Engl J Med 325 (1991) 551-555
186. Chilukuri S., and Rosen T. Management of acyclovir-resistant herpes simplex virus. Dermatol Clin 21 (2003) 311-320
187. Leung D.T., and Sacks S.L. Current recommendations for the treatment of genital herpes. Drugs 60 (2000) 1329-1352
188. Lalezari J.P., Drew W.L., Glutzer E., et al. Treatment with intravenous (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]-cytosine of acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with AIDS. J Infect Dis 170 (1994) 570-572
189. Snoeck R., Andrei G., Gerard M., et al. Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC). Clin Infect Dis 18 (1994) 570-578
190. Safrin S., Kemmerly S., Plotkin B., et al. Foscarnet-resistant herpes simplex virus infection in patients with AIDS. J Infect Dis 169 (1994) 193-196
191. Martinez V., Molina J.M., Scieux C., Ribaud P., and Morfin F. Topical imiquimod for recurrent acyclovir-resistant HSV infection. Am J Med 119 (2006) e9-e11
192. Brummitt C.F. Imiquimod 5% cream for the treatment of recurrent, acyclovir-resistant genital herpes. [comment]. Clin Infect Dis 42 (2006) 575
193. Bernstein D.I., Spruance S.L., Arora S.S., Schroeder J.L., and Meng T.C. Evaluation of imiquimod 5% cream to modify the natural history of herpes labialis: a pilot study. Clin Infect Dis 41 (2005) 808-814
194. Gilbert J., Drehs M.M., and Weinberg J.M. Topical imiquimod for acyclovir-unresponsive herpes simplex virus 2 infection. Arch Dermatol 137 (2001) 1015-1017
195. Drew W.L., Paya C.V., and Emery V. Cytomegalovirus (CMV) resistance to antivirals. Am J Transplant 1 (2001) 307-312
196. Gilbert C., and Boivin G. Human cytomegalovirus resistance to antiviral drugs. Antimicrob Agents Chemother 49 (2005) 873-883
197. Soderberg-Naucler C., and Emery V.C. Viral infections and their impact on chronic renal allograft dysfunction. Transplantation 71 Suppl (2001) SS24-SS30
198. Lu H., and Thomas S. Maribavir (ViroPharma). Curr Opin Investig Drugs 5 (2004) 898-906
199. Lowance D., Neumayer H.H., Legendre C.M., et al., International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. N Engl J Med 340 (1999) 1462-1470
200. Lake K.D. New prophylactic treatment strategy for cytomegalovirus disease. Am J Health Syst Pharm 60 (2003) S13-S16
201. Paya C., Humar A., Dominguez E., et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 4 (2004) 611-620
202. Yen H.L., Herlocher L.M., Hoffmann E., et al. Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrob Agents Chemother 49 (2005) 4075-4084
203. Hurt A.C., Iannello P., Jachno K., et al. Neuraminidase inhibitor-resistant and -sensitive influenza B viruses isolated from an untreated human patient. Antimicrob Agents Chemother 50 (2006) 1872-1874
204. Regoes R.R., and Bonhoeffer S. Emergence of drug-resistant influenza virus: population dynamical considerations. Science 312 (2006) 389-391
205. Komazin G., Ptak R.G., Emmer B.T., Townsend L.B., and Drach J.C. Resistance of human cytomegalovirus to the benzimidazole l-ribonucleoside maribavir maps to UL27. J Virol 77 (2003) 11499-11506
206. Evers D.L., Komazin G., Ptak R.G., et al. Inhibition of human cytomegalovirus replication by benzimidazole nucleosides involves three distinct mechanisms. Antimicrob Agents Chemother 48 (2004) 3918-3927
207. Moscona A. Oseltamivir resistance-disabling our influenza defenses. N Engl J Med 353 (2005) 2633-2636
208. Bowen E.F., Johnson M.A., Griffiths P.D., and Emery V.C. Development of a point mutation assay for the detection of human cytomegalovirus UL97 mutations associated with ganciclovir resistance. J Virol Methods 68 (1997) 225-234
209. Ducancelle A., Champier G., Alain S., Petit F., Le Pors M.J., and Mazeron M.C. A novel mutation in the UL54 gene of human cytomegalovirus isolates that confers resistance to foscarnet. Antivir Ther 11 (2006) 537-540
210. Chou S., Marousek G., Parenti D.M., et al. Mutation in region III of the DNA polymerase gene conferring foscarnet resistance in cytomegalovirus isolates from 3 subjects receiving prolonged antiviral therapy. J Infect Dis 178 (1998) 526-530
211. Boivin G., Goyette N., Gilbert C., and Covington E. Analysis of cytomegalovirus DNA polymerase (UL54) mutations in solid organ transplant patients receiving valganciclovir or ganciclovir prophylaxis. J Med Virol 77 (2005) 425-429
212. Baldanti F., Underwood M.R., Stanat S.C., et al. Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS. J Virol 70 (1996) 1390-1395
213. Drew W.L. Ganciclovir resistance: a matter of time and titre. Lancet 356 (2000) 609-610
214. Chrisp P., Clissold S.P., and Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. Drugs 41 (1991) 104-129
215. Erice A. Resistance of human cytomegalovirus to antiviral drugs. Clin Microbiol Rev 12 (1999) 286-297
216. Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med 353 (2005) 1363-1373
217. Suzuki H., Saito R., Masuda H., Oshitani H., Sato M., and Sato I. Emergence of amantadine-resistant influenza A viruses: epidemiological study. J Infect Chemother 9 (2003) 195-200
218. Shiraishi K., Mitamura K., Sakai-Tagawa Y., Goto H., Sugaya N., and Kawaoka Y. High frequency of resistant viruses harboring different mutations in amantadine-treated children with influenza. J Infect Dis 188 (2003) 57-61
219. Bright R.A., Shay D.K., Shu B., Cox N.J., and Klimov A.I. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 295 (2006) 891-894
220. Saito R., Sakai T., Sato I., et al. Frequency of amantadine-resistant influenza A viruses during two seasons featuring cocirculation of H1N1 and H3N2. J Clin Microbiol 41 (2003) 2164-2165
221. Ilyushina N.A., Govorkova E.A., and Webster R.G. Detection of amantadine-resistant variants among avian influenza viruses isolated in North America and Asia. Virology 341 (2005) 102-106
222. Cheung C.L., Rayner J.M., Smith G.J., et al. Distribution of amantadine-resistant H5N1 avian influenza variants in Asia. J Infect Dis 193 (2006) 1626-1629
223. Peiris J.S., Yu W.C., Leung C.W., et al. Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet 363 (2004) 617-619
224. Beigel J.H., Farrar J., Han A.M., et al. Avian influenza A (H5N1) infection in humans. N Engl J Med 353 (2005) 1374-1385
225. Kiso M., Mitamura K., Sakai-Tagawa Y., et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364 (2004) 759-765
226. Herlocher M.L., Truscon R., Elias S., et al. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J Infect Dis 190 (2004) 1627-1630
227. Monto A.S., McKimm-Breschkin J.L., Macken C., et al. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother 50 (2006) 2395-2402
228. Gubareva L.V., Webster R.G., and Hayden F.G. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants. Antimicrob Agents Chemother 45 (2001) 3403-3408